Mellor R, Lancaster K, Ritter A. Recovery from alcohol problems in the absence of treatment: a qualitative narrative analysis. Addiction. 2021 Jun;116(6):1413-23. doi: 10.1111/add.15288
Luo C, Sun J, Liu D, Sun B, Miao L, Musetti S, Li J, Han X, Du Y, Li L, Huang L, He Z. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett. 2016 Sep 14;16(9):5401-8. doi: 10.1021/acs.nanolett.6b01632
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.
Davis KL, Gutierrez B, Zyczynski T, Kaye JA. Real-world treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. JHEOR. 2015 Jan 6;2(2):119-30. doi: 10.36469/9894
Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction. 2014 Aug;109(8):1274-84. doi: 10.1111/add.12557
Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012 May 1;95(5):535-44.
Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012 Mar 1;95(3):263-73.
West R, Gilsenan A, Coste F, Zhou X, Brouard R, Nonnemaker J, Curry SJ, Sullivan SD. The ATTEMPT cohort: a multi-national longitudinal study of predictors, patterns and consequences of smoking cessation; introduction and evaluation of internet recruitment and data collection methods. Addiction. 2006 Sep 1;101(9):1352-61.